Sign in

RELX PLC REN.AS

Price 31.3 EUR
as of 2026-09-04
50/100
Constructive
Quality83
Growth58
Balance-sheet strength16
Valuation39
Momentum39
Income68

Composite 50/100; the shares have moved about 32% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.

Strongest counter-signal

Balance-sheet strength ranks 16/100 — a strong mark against it.

Case for

Quality ranks 83/100 — a strong point in its favour. Income ranks 68/100 — a moderate point in its favour. Growth ranks 58/100 — a slight point in its favour.

Case against

Balance-sheet strength ranks 16/100 — a strong mark against it. Valuation ranks 39/100 — a slight mark against it. Momentum ranks 39/100 — a slight mark against it.

What the company does RELX PLC provides information-based analytics and decision tools for professional and business customers across Risk, Scientific/Technical/Medical, Legal, and Exhibitions segments. It combines content, technology, and algorithms to help clients evaluate risk, access scientific data, navigate legal/regulatory frameworks, and connect at hybrid events.

Key financials RELX exhibits strong profitability with ROE 132%, ROA 13%, and ROCE 71%. Margins are robust: gross 66%, operating 32%, net 23%. Revenue growth is modest at 3%, but EPS growth is high at 24%. Debt/equity stands at 7.10 with interest coverage of 8.88.

Stock health Momentum is mixed: +13% over 6 months, but -23% from the 52-week high and RSI at 77.10 (overbought). Quality scores are excellent (82), income yield is 2.2%, and dividend payout is 54%. Valuation metrics (P/E 22.62, EV/EBITDA 14.54) suggest rich pricing.

Price vs fair value RELX trades at a PREMIUM of 30.50% versus our fair-value estimate of 23.38 and at a discount of 40.24% versus the analyst 12-month target of 47.15. - Trading at a 30.50% premium to fair-value estimate (provided fair-value estimate) - Trading at a 40.24% discount to analyst target (analyst count 2.0) - RSI at 77.10 indicates overbought conditions (RSI(14) 77.10) - Quality score of 81.6 supports premium valuation (Sideravia Quality 81.6) - High ROE 132% and net margins 23% justify premium pricing (ROE 131.9%, Net margins 23.3%)

Looking forward Forward P/E of 18.32 and PEG of 0.78 suggest reasonable earnings growth expectations. Exhibitions segment recovery and digital integration may drive future growth, but macro sensitivity and high valuation could limit upside. Monitor EPS growth and debt metrics for sustainability.

sideravia.comEvery stock argues both sides.
Research, not advice · sideravia.com/conflicts — read the policy

This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.

Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.